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Objectives: We aimed to investigate the motives, barriers and experiences of HIV-STAR study participants. The
HIV-STAR study was an analytical HIV treatment interruption trial (ATI) aiming to evaluate the origin of viral
rebound, conducted in Ghent, Belgium.
Methods: A mixed-method study was performed among 11 participants of the HIV-STAR study. Two self-
administered questionnaires with 32 and 23 items, respectively, assessed motives, barriers and experiences of
the research participants. In-depth interviews were conducted to further explore and understand topics that had
emerged from these surveys.
Results: Motives of ATI study participants were primarily related to the improvement of their own health per-
spectives and to their contribution to find an HIV cure. Barriers for ATI participation mostly related to practical
issues, such as difficulty in planning study visits. Ten out of 11 participants reported a very high overall satis-
faction and were willing to participate in another ATI. This satisfaction was predominantly linked to clear
communication and guidance. Invasive sampling during the ATI was less of a burden than anticipated by par-
ticipants. However, most participants underestimated the emotional impact of HIV treatment interruption, which
was associated with feelings of uncertainty and loss of control. Risk of HIV transmission because of viral rebound
was also mentioned as burdensome during this phase.
Conclusions: Involvement in an ATI was positively evaluated by HIV-STAR participants. Contributing to HIV cure
research outweighed the burden of study participation for most participants. The latter aspects were attenuated by
mutual decision making and the experience of empathy from the research team. Still, issues regarding privacy and
the psychosocial impact of treatment interruption, including sexuality and HIV transmissibility, should be
addressed in a better way.Introduction
Analytical treatment interruption trials (ATI) are of substantial
importance to HIV cure research. The lack of a specific biomarker of HIV
infection render ATI trials necessary to evaluate the efficacy of HIV cure
interventions and the effect of novel drugs/compounds on stable HIV
remission/cure, such as new latency reversing agents (LRAs).1 ATI trialszgent.be (M.-A. De Scheerder).
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evier Ltd. This is an open access aprovide critical information about time to viral rebound and in combi-
nation with extensive patient sampling provide broader insights
regarding the origin of this rebound. In addition, they can accelerate the
identification of potential biomarkers to predict viral rebound after
treatment interruption.2,3
The risk of HIV reservoir expansion due to ATI was reported to be
minimal in blood and brain, indicating that such trials are safe in terms of7 January 2021
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Fig. 1. Schematic overview of the study set-up. 1) Extensive sampling under cART. 2) Treatment interruption phase with monitoring up to viral rebound. 3) Analysis
of viral sequences isolated from samples from the 1st and 2nd study phase to determine the origin of viral rebound.
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impact of participation in ATI trials needs to be considered. Most ATIs
involve extensive and invasive sampling, potentially including lymph
node excisions, lumbar punctures and leukapheresis as well as frequent
study visits. Moreover, viral rebound during treatment interruption may
result in increased infectiousness.6,7 These issues represent potential
barriers to study participation in some PLHIV, and may render study
participation stressful and burdensome.
Contribution to the improvement of treatment options constitute the
scientific and societal interest of ATI but it should be weighed out against
the potential harm and burden to study participants.
Although previous research has shown high acceptance of HIV cure
research in people living with HIV (PLHIV),8–10 there are to date only
limited reports regarding the experience of participants in such trials.
To gain more insight in the potential burden of ATIs and to explore to
which extent the reality of their trial participation met their expectations,
we conducted a mixed-method study among participants of the HIV-
STAR study, an ATI conducted in Ghent, Belgium. In this sub-study, we
explored motives, barriers, expectations and experiences of study par-
ticipants by using two questionnaire surveys and subsequently performed
in-depth interviews for clarifications. Based on our findings, we propose
a checklist that can be used to guide future clinical trials.
Methods
Study population and procedures of the HIV-STAR study
The HIV-STAR study (NCT02641756) was initiated in 2015. Exten-
sive tissue sampling of HIV- infected patients was performed both on
combination antiretroviral therapy (cART) as well as during structured
cART interruption in order to investigate the origin of viral rebound.
Eligibility criteria included the following: (i)HIV-seropositivity without a
history of AIDS defining conditions, (ii)CD4 T-cell count above 500/μl,
(iii) an undetectable plasma viral load (<20 copies/ml) during the last 2
years, without any blips observed in the last 6 months and (iiii) on an
ART regimen containing an integrase inhibitor for at least 3 months at the
first sampling. PLHIV who met these inclusion criteria were recruited
during routine HIV outpatient consultations at the HIV Reference Center
in Ghent. Prior to study enrollment, participants received extensive in-
formation about the study procedures during two visits with a study
physician, who was different from the treating physician. The mean time
between the first pre-enrollment visit and study enrollment was 3
months. An independent senior staff physician and a psychologist were
available for consult upon request of either the study physician or the
potential study participant. If this independent assessment revealed
psychological vulnerability, incompatible with study participation, this
was reported as screen failure. Prior to inclusion in the study, participants
were informed about the potential risks of sampling and of treatment
interruption as well as about the lack of personal benefit.2
Fig. 1 gives a schematic overview of the of two phases of the HIV
STAR study. During the first phase, participants were extensively
sampled while on cART. After approximately three months, participants
were scheduled for the second part of the study. During this second
phase, participants were instructed to stop cART. Viral parameters were
monitored 2–3 times per week until the occurrence of viral rebound.
Participants were instructed to restart cART immediately after collection
of the final study sample upon viral rebound. The final study visit was
conducted three months after the patient’s viral load had dropped again
to an undetectable level.Data collection
For this sub-study, we assessed motives, barriers, expectations and
experiences of participants in the HIV-STAR study. First, all subjects self-
completed a questionnaire including 32 items on motives, barriers and
expectations of study participation at enrollment (“baseline question-
naire”). A second survey was conducted during the final study visit and
consisted of 23 items to assess motives and investigate the overall
satisfaction and experiences of study participation (“exit questionnaire”).
Questionnaire items were based on previous literature12 and comments
of the local medical ethical committee of Ghent University Hospital. In
the context of external validity, these surveys were reviewed by an in-
dependent psychologist with experience in HIV care. The ATI took place
between June 2016 and July 2017 and all participants completed the
questionnaires immediately before and after study participation. Both
questionnaires and responses are listed in Supplement 1.
In August 2018, 1–2 years after the ATI, we conducted semi-
structured in-depth interviews (IDI) to gain more insight in issues that
had emerged from the questionnaires. For this, all HIV-STAR study par-
ticipants were invited for a face-to-face interview. The IDIs lasted
approximately 30–60 min and were conducted in Dutch by a single
external physician whowas not further involved in the study execution or
the follow-up of participants (WvB). All IDIs were audio-recorded and
transcribed verbatim. Motives and barriers for study participation were
explored, as well as positive and negative experiences of each study
phase. The interview guide can be found in Supplement 2.
The statistical computer program IBM SPSS Statistics for Windows
(IBM Corp, Armonck, NY, USA) was used for quantitative data analysis.
Tables were extracted in Microsoft excel. The scale was 1->5 or 1->4, the
highest scores indicating full agreement with the statement.
Qualitative data analysis was performed by three researchers (MDS,
WvB, UD). MaxQDA version 12.0 was used for qualitative data analysis
using coding and content analysis.13 All transcripts were coded using an
open-coding process by two independent coders (MDS, WvB). Variability
in coding was discussed until reaching consensus between coders. Crys-
tallization of similar codes was eventually performed to generate one list
of codes with an unambiguous definition, as agreed by all researchers.
These codes were then categorized into themes reflecting motives,
Table 1
Relevant demographics of the HIV-infected study participants.
Subject-
ID
Race Gender Age CD4 nadir (cells/
μl)
Viral load zenith (log10 HIV-1 c/
m)




Time to viral rebound
(days)
STAR2 White M 38 438 5,08 NA 4 36
STAR3 White M 52 331 5,53 3 3 28
STAR4 White M 36 142 4,31 NA 11 20
STAR5 White M 39 308 4,77 3 3 15
STAR6 White M 41 378 4,82 4 3 19
STAR7 White M 40 421 4,8 11 3 21
STAR8 White M 40 400 4,64 11 8 21
STAR9 White M 32 405 5,01 9 6 21
STAR10 White M 54 327 5,49 20 11 21
STAR11 White M 37 432 3,62 9 2 28
STAR12 White F 56 348 3,23 7 6 25
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study.
Ethical approval
This study was approved by the local medical ethical committee of the
University Hospital of Ghent (Belgian registration number:
B670201525474). Participation was voluntary and every participant
provided a written informed consent prior to study enrollment. Partici-
pants received €1000 as a compensation for the time spent in the hospital
and travel expenses. No additional incentive was given for participation
in the in-depth interview.
Results
The HIV-STAR study population consisted of one female and ten male
participants. Their median age was 40 years (range of 32–56 years).
Relevant demographics are listed in Table 1. All eleven participants
completed both the baseline and exit questionnaires. Of these eleven
participants, nine were interviewed. The two left participants (STAR
4–11) were not able to schedule the interview because of other com-
mitments but had indicated willingness to participate to the interviews.
Motives for study participation
In the baseline questionnaire, it became clear that gaining more
insight into their own health proved to be an important motive for HIV-
STAR study participants. Five participants reported that they hoped that
their involvement would improve their own health, and four participants
believed that study participation would substantially contribute to the
likelihood of future individual HIV cure. Three participants thought that
study participation would result in receiving more medical help for HIV
or other health issues, and three participants supposed that they would
be prioritized if new treatment options would become available. One
participant felt that study participation would allow him to stop taking
antiretroviral therapy, thus resulting in a functional cure. In total, three
participants felt that study participation would turn them into a better
person. All participants agreed that study participation would help other
patients. In the exit questionnaire, nine participants reported that sci-
entific progress and contribution in achieving new knowledge was an
important motive for study participation. All participants were eager to
receive the study results. This was also a motivation to participate in
future trials. All but one participant expressed interest in future projects
and HIV cure research. Ten participants would reengage in similar
projects.
The subsequent interviews provided additional, more altruistic, mo-
tives for study participation. Most participants mentioned appreciating
the care received after the diagnosis of HIV. They viewed participation in
a scientific study as a way to show their appreciation towards their health
care professionals. Some participants felt themselves a burden to society,
as their health care was perceived to be very expensive. They considered3
participation in the HIV-STAR study as a return service to society.
Another interesting line of thought, emerging from the interviews, was
the consideration that individual sacrifices are required in order to move
science forward.
“I am a huge cost for society, this is the least I can do.”
“If no one participates in these things, we will never book progress in
research.”
One participant mentioned seeking a better relationship with his
health care provider as his motive for participation. He hoped that he
would be prioritized once a cure became available. For the single woman
included in the study, her main motive to participate was women rep-
resentation in HIV research.
For none of the participants had the financial incentive provided,
emerged as a principal motive for study participation. Most participants
agreed that the amount of financial compensation provided was suffi-
cient. Still, one participant indicated that participation to future trials
would depend on a higher incentive fee.
Barriers for study participation and continuation
At first, time was one of the major barriers for study participation.
Indeed, the baseline questionnaire revealed that the majority of partici-
pants (7/11) thought that study participation would be too time-
consuming. Second, seven participants experienced nervousness about
the invasive nature of the tissue sampling. None of the participants
worried about the psychological and/or emotional impact of the antire-
troviral treatment interruption, and no one reported fear for the emer-
gence of drug-resistance virus. Still, three participants expected the study
to have an important impact on their relationship and/or social life. Nine
participants mentioned that they did not have the intention to reveal
study participation to their relatives or close friends. In this context, four
of them also expected a negative reaction. Nevertheless, all participants
having a relationship at the time of the study, shared their study
participation with their partners.
At the time of the interviews, it became clear that main hesitations
towards study participation consisted of concerns about personal avail-
ability, fear regarding the invasive nature of the investigations, harm of
privacy and dealing with an unknown research team. In terms of privacy,
some participants stated they were afraid to (potentially) get in contact
with other study participants. They did not want their HIV status to be
disclosed to people other than health care providers. The provision of
adequate information and good guidance by the research team were
mentioned as factors that helped them overcome potential barriers.
Finally, a high level of trust in the research team was reported.
“Knowing the virus is coming back, you have faith and you put your faith
in the study team, and you hope or trust that stopping the medication will
not hurt you.”
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In the exit questionnaire, ten out of 11 participants were very satisfied
about their involvement in the study. These ten participants were also
willing to participate in future similar trials and felt that their expecta-
tions prior to study participation were met by the actual experience.
Eight participants reported satisfaction with the overall study organiza-
tion, and ten participants did not encounter difficulties planning the
study visits. All participants found that their privacy was respected
during the study.
Only one participant reported an overall low satisfaction with study
participation. In particular, he pointed out negative experiences with the
study organization, information provided and guidance during the study.
He had no interest in participating in future trials. Despite this overall
negative experience, this participant did not report any physical or
emotional consequences.
During the interviews, the overall high satisfaction of study partici-
pants was primarily linked to positive experiences with the research
team. Specifically, the flexibility and accessibility of the research team
were highlighted. Participants highly valued the personal approach,
making them feel comfortable and secure. One of the participants
recalled a negative experience with a study nurse, when she accidentally
identified two other study participants. Concerning the logistics, partic-
ipants felt that the study visits were time consuming, and indicated that
the hospital administration was not efficient and was prone to
improvement.
“It [the approach of the research team] provided a sense of security, ef-
ficiency and not being impersonal, and for me this was very important.”
Moreover, participants provided insight into the support they
received from their personal environment during the interviews. Most
participants indicated that they kept their study participation private (n
¼ 6). Among those who disclosed their study participation to relatives,
some reported a supportive attitude from close family or friends, while
others experienced skeptic reactions from relatives about the potential
impact and safety of the study.Impact of invasive investigations
While seven participants anticipated the sampling investigations as a
burden in the baseline questionnaire, only two reported actual experi-
ence of burden in the exit questionnaire. Ten participants indicated the
information received prior to the study being in line with their actual
experience. For most, fear prior to the investigations proved worse than
the actual physical burden, such as pain or discomfort.
During the interviews, the most frequently reported negative physical
experience was discomfort when lying still during the leukapheresis (n¼
3), followed by a painful wound after inguinal lymph node excision (n ¼
2) and headache following lumbar puncture (n ¼ 1). These complica-
tions, although limited, were identified as the reason for a higher impact
of the interventions than the one initially expected.Impact of antiretroviral treatment interruption and continuation
In the baseline questionnaire, ten participants agreed with the state-
ment that stopping HIV treatment could potentially result in HIV trans-
mission to sex partners. In the exit questionnaire, eight of these
participants reported not to have engaged in unprotected sexual activity
when off HIV treatment. In the same questionnaire, five participants
described the treatment interruption in the following words: alienating,
strange, burdensome and stressful. Preoccupation about becoming
detectable again was pointed out by three participants.
During the interviews, two participants mentioned that they had to
change their HIV medication to an integrase inhibitor containing
regimen prior to study participation. For one participant this resulted in4
significant side effects, to such extent, that he needed to reveal his
participation and HIV status to his boss because of the impact on his
work. This incident was perceived as very burdensome and affected his
quality of life.
Overall, most participants experienced the treatment interruption
phase as the most challenging part of the study. Especially the period of
post-ATI intense follow-up with frequent hospital visits and the feeling of
uncertainty about how long it would take before their viral load would
rebound rendered this period intense. One participant felt that becoming
detectable again represented a personal confrontation with the reality of
being HIV positive.
“Still now, whenever I come here, to the clinic, I am confronted with the
reality of the infection.”
In addition, the interviews revealed that study participation led to
changes in sexual behavior in order to prevent onward transmission of
HIV. One participant changed his relationship from open to closed. Some
participants who normally did not (always) use a condom during sex,
started using condoms, and others mentioned that they rejected sex or
had less sex during treatment interruption. One participant reported a
decrease in libido. Most participants did not experience these changes as
burdensome, as they found comfort in the information that this would
only be temporary. Participants who did not change their sexual behavior
indicated that their sex partners were already HIV positive (n¼ 2) or that
the sex partner did not want to use condoms despite being informed
about the risk of transmission (n ¼ 1). All participants acknowledged the
importance of counseling and the provision of information about sexual
intercourse in the context of study participation and/or treatment
interruption.
Negative self-perceptions associated with becoming detectable again
were also mentioned during the interviews. They pointed out an
awareness of feeling in control of the virus when on treatment. This
resulted in negative thoughts and feelings about treatment interruption.
It was described as if their body was not fighting the virus anymore, as if
they let the virus take over. One participant described it as feeling ‘dirty’.
“For the first time in 10 years I am not fighting the virus anymore and I
allow the virus to fight me again.”Discussion
This study reports the motives, barriers and experiences of partici-
pants in a monocentric ATI trial in Ghent, Belgium. Helping to find a cure
for HIV proved to be one of the main motives prior to participation,
resulting in not only individual, but also societal benefits. Almost half of
the participants hoped that study participation would benefit their per-
sonal health and would substantially improve their own likelihood of
achieving an HIV cure. After having completed the study, the exit ques-
tionnaire revealed feeling of scientific progress and contribution in
achieving new knowledge as the most important motives for study
participation. In line with previous research,8–10 these findings demon-
strate that HIV cure is high on the agenda for PLHIV, despite increased
accessibility and tolerance of cART regimens, Undetectable ¼ Untrans-
mittable campaigns and the availability of pre-exposure prophylaxis
(PrEP).
We conducted a stringent selection of potential candidates, based not
only on virological and immunological criteria, but also on the psycho-
logical vulnerability of participants. The latter was assessed by an inde-
pendent senior physician and/or a psychologist if judged necessary by
the study team. Potential candidates were not included in this study
protocol if this independent assessment revealed psychological vulnera-
bility, incompatible with study participation. Still, we were surprised by
the number of participants that were driven by the motivation of
potentially getting cured and/or improving their own health, even after
being well informed that this was not a cure trial and that there was no
M.-A. De Scheerder et al. Journal of Virus Eradication 7 (2021) 100029personal benefit to be expected. Despite these presumably alarming an-
swers, all participants remained in care and on treatment after the trial
without adherence issues. However, we want to emphasize the impor-
tance of the informed consent, of autonomy and of the substantial risk for
therapeutic misconceptions, as crucial features in conducting this type of
trials and of trials in general. Especially, we believe that providing reg-
ular information to participants during the trial prevents misconceptions
or unrealistic expectations.
Interestingly, our results show that altruism - supporting a pathway
towards cure - is a key motivator in order to participate in these trials, as
observed in previous studies.11,14,15 Some of these reports highlight that
while treated HIV-infection is considered to be a low burden disease by
health professionals, some PLHIV still experience their health status as
vulnerable.14 For instance, among Dutch HIV-positive men having sex
with men (MSM), one-third perceives living with HIV as burdensome,
and 82% would be relieved if a cure existed.16 Considering these moti-
vational pathways, both individual and societal, a recent publication of
Julg et al.20 stresses the importance of including various stakeholders and
active community contributors in the process of trial development. These
panels should guarantee a strong scientific rationale in order to support
any intervention (e.g., ATI), as well as maximize research progress and
minimize both health and non-health related risk for participants.
Initial barriers for study participation included concerns about the
time-consuming character of the study, given that some participants
feared that it would temporarily impact their work or social life.
Adequate time management, clear communication and flexibility of the
research team were mentioned to have contributed to overcome this
barrier. For instance, home venipunctures through his general practi-
tioner were arranged for one participant. Unfortunately, some other
concerns could not be addressed, such as the compulsory but time-
consuming hospital administration procedure prior to every study visit.
Another barrier for study participation was the concern about privacy
and anonymity. Revealing study participation would also reveal one’s
HIV status, and most participants had never disclosed their status. In the
set-up of ATIs this needs to be acknowledged and discussed with po-
tential participants, and additional effort should be made to guarantee
anonymity.
In line with a previous report, the overall satisfaction rate of our study
population was high.12 All but one had realistic expectations of study
burden, outcome and benefits, resulting in a high proportion of partici-
pants that would re-engage in future trials. Only one participant reported5
a negative experience of his participation. Interestingly, the main motive
for study participation in this case was to gain a better relationship with
the health care provider, perceived to facilitate future medical prioriti-
zation. Such inappropriate expectations need to be addressed prior to
study enrollment in order to avoid future disappointment in these par-
ticipants. Therefore, we recommend engaging an independent study
physician, not directly involved in the individual patient care, in such
trials.
Another important point is the treatment interruption phase, as dis-
cussed in several reports debating the ethics of cure research.11,17
Noteworthy, this aspect was underestimated the most by participants in
our study at baseline, in terms of its negative emotional and psycholog-
ical impact. We, therefore, suggest that potential feelings of uncertainty
and loss of control due to treatment interruption should be discussed
prior to trial initiation. Furthermore, emphasis should be put on the as-
pects of infectiousness and risk of onward HIV transmission during
treatment interruption. Most participants changed their sexual behavior
in a way to reduce the risk of sexual transmission. Future trials should
propose the use of PrEP for partners of participants in ATIs. At the time of
our trial, PrEP was not yet available in Belgium.
In our study, participants did not experience a high burden from the
intensive and invasive sampling phase, although many expected this
phase to be the most challenging. Several potential and eligible candi-
dates for our trial were not enrolled, as they refused to undergo these
investigations. Conveying the view of previous trial participants that
such issues were eventually experienced as much less burdensome than
expected (e.g., by way of testimonials) might increase participation
willingness in future trials. To cope with this anxiety, we chose to
perform all invasive investigations under general anesthesia at one time
point in our trial. This was positively evaluated by the participants.
We wish to acknowledge the limitations of the study. Although small
numbers of participants are a characteristic feature of treatment-
interruption & cure trials, this limits the relevance of statistical ana-
lyses. Therefore, our quantitative analysis could not take into account
socio-demographic aspects that might have influenced the responses.
Further, our sample was predominantly indigenous and almost exclu-
sively concernedMSM, hampering generalization of our findings to other
social-demographic contexts. Finally, we only included in the evaluation
PLHIV who participated in the trial, making their responses subject to
potential bias in comparison to those having refused to participate or
those that were held back after psychological evaluation.
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In spite of potential barriers and negative experiences of ATIs, cure
research seems of high importance to PLHIV. The vast number of par-
ticipants willing to participate in future cure trials implies that contrib-
uting to finding a cure for HIV outweighs the burden of study
participation. Based on our results, future trials should incorporate a
strict inclusion policy, shared decision making and an involved research
team to meet the personal needs of participants. Issues regarding privacy
and the psychosocial impact of treatment interruption, including sexu-
ality and HIV transmissibility, should be addressed specifically. PrEP
should be offered to seronegative sexual partners of trial participants.
Based on our findings, we propose the following checklist to guide future
similar clinical trials, abbreviated as the acronym SPONSOR.
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